Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 07/28/26
Incyte Reports Second Quarter 2026 Financial Results and Provides Business UpdatesBusiness Wire • 07/28/26
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?Zacks Investment Research • 07/24/26
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 07/21/26
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® TechnologyPRNewsWire • 07/20/26
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat CancersBusiness Wire • 07/17/26
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease TypesBusiness Wire • 07/13/26
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology PortfolioBusiness Wire • 07/06/26
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?Zacks Investment Research • 06/29/26
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic DermatitisBusiness Wire • 06/26/26
Here Are Monday's Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, SpaceX, and More24/7 Wall Street • 06/22/26
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Business Wire • 06/19/26